Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2 Urinary Bladder Neoplasms 1 Recurrence 1

Interventions

Cyclophosphamide 49 fludarabine 36 Dexamethasone 35 venetoclax 29 pembrolizumab 26 Rituximab 21 Lenalidomide 18 pomalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 11 carfilzomib 11 Temozolomide 11 Cisplatin 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Injections 9 Azacitidine 9 selinexor 8 Vincristine 8 Carboplatin 8 Bortezomib 8 obinutuzumab 7 Immunotherapy, Adoptive 7 Bevacizumab 7 zanubrutinib 6 ruxolitinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Dutasteride × 1 year × Clear all

NCT07420517 2026-03-30

DutaBCa-1

CHU de Quebec-Universite Laval

Phase 2 Recruiting

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡